	US 12,453,746 B2
	Use of akkermansia muciniphila in preparation of pharmaceutical composition or health care product composition for improving metabolic syndrome
Yangyang Liu, Guangzhou (CN); Lijun Zheng, Guangzhou (CN); Ping Li, Guangzhou (CN); Gaobo Kuang, Guangzhou (CN); Xiaomin Yi, Guangzhou (CN); Ye Wang, Guangzhou (CN); and Fachao Zhi, Guangzhou (CN)
Assigned to GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD., Guangzhou (CN)
Appl. No. 18/871,201
Filed by GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD., Guangzhou (CN)
PCT Filed Jun. 8, 2023, PCT No. PCT/CN2023/099224 § 371(c)(1), (2) Date Dec. 3, 2024, PCT Pub. No. WO2023/237067, PCT Pub. Date Dec. 14, 2023.
Claims priority of application No. 202210642471.7 (CN), filed on Jun. 8, 2022.
Prior Publication US 2025/0170187 A1, May 29, 2025
Int. Cl. A61K 35/74 (2015.01); A61K 31/40 (2006.01); A61P 3/00 (2006.01)

CPC A61K 35/74 (2013.01) [A61K 31/40 (2013.01); A61P 3/00 (2018.01)]

20 Claims

1. A method for improving metabolic syndrome, the method comprising: administering to a subject a therapeutically effective amount of Akkermansia muciniphila AM06, or a therapeutically effective amount of a pharmaceutical composition comprising the Akkermansia muciniphila AM06, wherein the Akkermansia muciniphila AM06 was deposited in the China General Microbiological Culture Collection Center on Jun. 28, 2021 with a deposit number of CGMCC No. 22793;

wherein improvement of the metabolic syndrome comprises at least one of preventing and treating metabolic syndrome.